Patients qualify for initial intravenous option in children. Ongoing therapy however is children with ITP do not require IVIg therapy; immunoglobulin (IVIg) therapy with not indicated. (A) indeed, no treatment at all is required for many bleeding children. Corticosteroids are the alternative AND SWG noted that above 50, life threatening therapy to IVIg. bleeding is unlikely to be due to the low platelets Thrombocytopoenia <50 x 109/L. and vessel injury must be sought. (A) Acute ITP ITP with platelet count <30 x 109/L with Life-threatening bleeding due to significant bleeding. thrombocytopenia; Patients qualify for initial IVIg therapy when current platelet count is <30 x 109/L. OR AND Thrombocytopenia with platelet count Moderate to severe mucosal and/or <30x109/L and moderate to severe cutaneous bleeding. mucosal and/or cutaneous bleeding. A repeat dose at 24–48 hours may be given if response is inadequate and recurrent Chronic ITP symptomatic thrombocytopenia occurs. The duration of response to the initial dose is Life-threatening bleeding due to typically two to four weeks. thrombocytopenia; Chronic ITP with life-threatening bleeding. OR Patients qualify for initial IVIg therapy when ITP has been diagnosed for longer than In responsive patients for treatment of months thrombocytopenia (<30x109/L) with AND moderate to severe bleeding symptoms where other therapeutic options have Patient has life-threatening bleeding due to failed or are contraindicated; thrombocytopenia <50 x 109/L.
children with ITP do not require IVIg therapy; indeed, no treatment at all is required for many children. Corticosteroids are the alternative therapy to IVIg. Acute ITP Life-threatening bleeding due to thrombocytopenia; OR Thrombocytopenia with platelet count <30x109/L and moderate to severe mucosal and/or cutaneous bleeding. Chronic ITP Life-threatening bleeding due to thrombocytopenia; OR In responsive patients for treatment of thrombocytopenia (<30x109/L) with moderate to severe bleeding symptoms where other therapeutic options have failed or are contraindicated; Patients qualify for initial intravenous immunoglobulin (IVIg) therapy with bleeding AND Thrombocytopoenia <50 x 109/L. ITP with platelet count <30 x 109/L with significant bleeding. Patients qualify for initial IVIg therapy when current platelet count is <30 x 109/L. AND Moderate to severe mucosal and/or cutaneous bleeding. A repeat dose at 24–48 hours may be given if response is inadequate and recurrent symptomatic thrombocytopenia occurs. The duration of response to the initial dose is typically two to four weeks. Chronic ITP with life-threatening bleeding. Patients qualify for initial IVIg therapy when ITP has been diagnosed for longer than months AND Patient has life-threatening bleeding due to thrombocytopenia <50 x 109/L. option in children. Ongoing therapy however is not indicated. (A) SWG noted that above 50, life threatening bleeding is unlikely to be due to the low platelets and vessel injury must be sought. (A)
immune-thrombocytopenic-purpura-%28itp%29-in%20children%2015%20years%20and%20younger_0.DOCX